Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse (HGNS+T)
The goal of this clinical trial is to learn whether removing the tonsils at the time of hypoglossal nerve stimulation improves treatment of obstructive sleep apnea in adults whose airway collapses from the side of the upper airway during sleep. The main questions it aims to answer are:
- Does hypoglossal nerve stimulation combined with tonsillectomy reduce the severity of obstructive sleep apnea more than hypoglossal nerve stimulation alone?
- Does tonsillectomy improve how effectively hypoglossal nerve stimulation opens and stabilizes the upper airway?
Researchers will compare participants who receive hypoglossal nerve stimulation with tonsillectomy to participants who receive hypoglossal nerve stimulation alone.
Participants will:
- Complete sleep studies, questionnaires, and other assessments before and after treatment
- Be randomly assigned to receive hypoglossal nerve stimulation either with or without tonsillectomy
- Return for follow-up visits and sleep testing to evaluate treatment effectiveness
- In a subset of participants, complete additional overnight testing to measure how treatment changes upper-airway collapsibility
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Obstructive sleep apnea (OSA) is commonly treated with hypoglossal nerve stimulation (HGNS), but treatment efficacy is substantially reduced in patients with complete oropharyngeal lateral wall (OPLW) collapse. HGNS primarily enlarges the airway by protruding the tongue and is therefore most effective in patients with anteroposterior patterns of airway collapse. Tonsillectomy reduces tissue contributing to lateral pharyngeal narrowing and may complement the mechanism of HGNS by addressing residual lateral wall obstruction. Preliminary clinical data suggest that combining tonsillectomy with HGNS substantially improves treatment response compared with HGNS alone in patients with OPLW collapse, but this strategy has not been evaluated in a randomized clinical trial.
This prospective, randomized controlled trial will enroll 72 adults with moderate-to-severe OSA, complete OPLW collapse identified on drug-induced sleep endoscopy, and candidacy for both HGNS implantation and tonsillectomy. Participants will be randomized 1:1 to receive either concurrent HGNS implantation plus tonsillectomy or HGNS implantation alone. All participants will undergo standard postoperative device activation and titration. The primary efficacy endpoint will be assessed after approximately one month of optimized HGNS therapy using sleep studies and patient-reported outcomes. Participants in the HGNS-alone group with persistent OSA may subsequently undergo delayed tonsillectomy as part of standard clinical care, permitting additional within-subject mechanistic comparisons.
The primary objective is to determine whether concurrent tonsillectomy improves the effectiveness of HGNS in reducing OSA severity compared with HGNS alone. Secondary objectives are to determine whether tonsillectomy enhances HGNS-induced improvements in upper-airway collapsibility and to evaluate whether tonsillectomy modifies the physiological effects of HGNS beyond the effects of either treatment alone. In an optional mechanistic substudy, approximately 30 participants will undergo detailed physiological sleep studies to measure pharyngeal collapsibility using gold-standard techniques, providing insight into the mechanisms underlying any observed improvement in clinical outcomes.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Dillon Gilbertson, BASc
- Telefonnummer: 617-732-6488
- E-Mail: dgilbertson@bwh.harvard.edu
Studieren Sie die Kontaktsicherung
- Name: Daniel Vena, PhD
- Telefonnummer: 16178520719
- E-Mail: dvena@bwh.harvard.edu
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Brigham and Women's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of obstructive sleep apnea with apnea-hypopnea index (AHI) ≥ 15 events/hour
- Complete oropharyngeal lateral wall (OPLW) collapse identified on DISE
- Candidate for HGNS implantation based on standard clinical criteria
- Presence of small (1-2+) tonsils and eligibility for tonsillectomy
- Untreated OSA at the time of enrollment
- Willing and able to provide written informed consent
Exclusion Criteria:
- Absence of tonsils
- Presence of large tonsils (3-4+; not eligible for HGNS)
- Predominant central or mixed sleep apnea (>25% central or mixed events)
- Any unstable or serious medical condition that, in the opinion of the investigator, would increase risk or interfere with study participation
- Ineligibility for HGNS implantation based on standard clinical or surgical criteria
- Inability to comply with study procedures or follow-up assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: HGNS plus tonsillectomy
HGNS plus concomitant tonsillectomy
|
Tonsillektomie
HGNS alone (without concomitant tonsillectomy)
|
|
Aktiver Komparator: HGNS
HGNS alone (without concomitant tonsillectomy)
|
HGNS alone (without concomitant tonsillectomy)
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percent reduction in apnea-hypopnea index (AHI)
Zeitfenster: 1 month of optimized therapy.
|
Percent reduction in the apnea-hypopnea index (AHI), measured by overnight polysomnography, from baseline to the primary follow-up sleep study.
Higher values indicate greater improvement in obstructive sleep apnea.
|
1 month of optimized therapy.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Absolute change in apnea-hypopnea index
Zeitfenster: 1 month of optimized therapy.
|
Absolute change in the apnea-hypopnea index (AHI), measured in events per hour by overnight polysomnography, from baseline to the primary follow-up sleep study.
Negative values indicate improvement in obstructive sleep apnea.
|
1 month of optimized therapy.
|
|
Treatment success
Zeitfenster: 1 month of optimized therapy
|
Treatment success is defined as a ≥50% reduction in the apnea-hypopnea index (AHI) from baseline and a follow-up AHI <15 events per hour.
The outcome is reported as the proportion of participants meeting this definition (0-100%), with higher values indicating greater treatment success.
|
1 month of optimized therapy
|
|
Change in Sleep Apnea Hypoxic Burden from Baseline
Zeitfenster: 1 month of optimized therapy
|
Sleep apnea hypoxic burden will be calculated from overnight polysomnography using the validated Azarbarzin method (PMID: 30376054) as the cumulative area under the oxygen desaturation curve associated with apneas and hypopneas, normalized to total sleep time and expressed as %min/hour.
Higher values indicate greater hypoxic burden.
|
1 month of optimized therapy
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PROMIS Sleep Disturbance
Zeitfenster: 1 month of optimized therapy
|
The PROMIS Sleep Disturbance Short Form 8b assesses perceptions of sleep quality, sleep depth, and difficulties with sleep.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater sleep disturbance (worse outcome).
|
1 month of optimized therapy
|
|
PROMIS Sleep-Related Impairment
Zeitfenster: 1 month of optimized therapy
|
The PROMIS Sleep-Related Impairment Short Form 8a assesses daytime impairment associated with poor sleep, including sleepiness, fatigue, and reduced alertness.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater sleep-related impairment (worse outcome).
|
1 month of optimized therapy
|
|
PROMIS Fatigue
Zeitfenster: 1 month of optimized therapy
|
The PROMIS Fatigue Short Form 7a assesses the experience and impact of fatigue on daily functioning.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater fatigue (worse outcome).
|
1 month of optimized therapy
|
|
Sleep apnea quality of life
Zeitfenster: 1 month of optimized therapy
|
The Sleep Apnea Quality of Life Index (SAQLI) assesses disease-specific quality of life in obstructive sleep apnea.
Total scores range from 1 to 7, with higher scores indicating better sleep-related quality of life (better outcome).
|
1 month of optimized therapy
|
|
Epworth sleepiness scale
Zeitfenster: 1 month of optimized therapy
|
The Epworth Sleepiness Scale assesses subjective daytime sleepiness.
Total scores range from 0 to 24, with higher scores indicating greater daytime sleepiness (worse outcome).
|
1 month of optimized therapy
|
|
VAS treatment satisfaction
Zeitfenster: 1 month of optimized therapy
|
Participants rate overall satisfaction with treatment on a 0-10 visual analog scale, where 0 indicates not at all satisfied and 10 indicates completely satisfied.
Higher scores indicate greater treatment satisfaction (better outcome).
|
1 month of optimized therapy
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Huyett P, Kent DT, D'Agostino MA, Green KK, Soose RJ, Kaffenberger TM, Woodson BT, Huntley C, Boon MS, Heiser C, Birk A, Suurna MV, Lin HS, Waxman JA, Kezirian EJ. Drug-Induced Sleep Endoscopy and Hypoglossal Nerve Stimulation Outcomes: A Multicenter Cohort Study. Laryngoscope. 2021 Jul;131(7):1676-1682. doi: 10.1002/lary.29396. Epub 2021 Jan 14.
- Vena D, Op de Beeck S, Yang H, Sumner J, Mann D, Wang TY, Aishah A, Azarbarzin A, Messineo L, Calianese N, Alex R, Esmaeili N, Vanderveken OM, White DP, Wellman A, Huyett P, Sands SA. Lateral wall collapse from sleep endoscopy and airflow shape predicts hypoglossal nerve stimulation efficacy in obstructive sleep apnoea. Eur Respir J. 2025 Oct 7;66(4):2500236. doi: 10.1183/13993003.00236-2025. Print 2025 Oct.
- Huyett P, Wellman A, Caruso V, Sumner J, Aishah A, Azarbarzin A, Sands S, Vena D. Combination Tonsillectomy and Hypoglossal Nerve Stimulation for Sleep Apnea Patients With Oropharyngeal Lateral Wall Collapse. Otolaryngol Head Neck Surg. 2024 Dec;171(6):1904-1910. doi: 10.1002/ohn.950. Epub 2024 Aug 27.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2026P000343
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .